1127119-18-9

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 

Downstream Products

• 1392137-46-0 6-(4-(1H-tetrazol-1-yl)phenyl)-3-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine 
• 1392137-66-4 5-(4-(1H-tetrazol-1-yl)phenyl)-N-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-3-nitropyridin-2-amine 
• 1392137-67-5 5-(4-(1H-tetrazol-1-yl)phenyl)-N₂-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)pyridine-2,3-diamine 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors

SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene, which affects the transduction of multiple signaling pathways, including RAS-ERK, PI3K-AKT and JAK-STAT. SHP2 also plays an important role in the programmed cell death pathway (PD-1/PD-L1). Studies have shown that SHP2 is associated with a variety of cancers, including breast, liver and gastric cancers. Therefore, the development of SHP2 inhibitors has attracted extensive attention. In this study, based on the known inhibitor 1 (SHP099), novel SHP2 inhibitors were designed by means of scaffold hopping, and 35 pyridine derivatives as SHP2 inhibitors were found. The in vitro enzyme activity assay was performed on these compounds, and multiple selective SHP2 inhibitors with activity potency similar to that of SHP099 were obtained. Among them, compound (2-(4-(aminomethyl)piperidin-1-yl)-5-(2,3-dichlorophenyl)pyridin-3-yl)methanol (11a) was the most potent and highly selective SHP2 inhibitor with an in vitro enzyme activity IC50 value of 1.36 μM. Fluorescence titration assay verified that 11a bound directly to SHP2 protein. Subsequently, cell assay of representative compounds showed that these compounds could effectively inhibit the proliferation of Ba/F3 cells. In addition, the pharmacokinetic characteristics of the designed compounds were analyzed by the in silico ADMET prediction. Molecular docking study provided more detailed information on the binding mode of compounds and SHP2 protein. In brief, this study reported for the first time that pyridine derivatives as novel SHP2 inhibitors had good inhibitory activity and selectivity, providing new clues for the development of small molecule SHP2 inhibitors.

BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS

The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula (I), pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.